ICK-Gyn: Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
ICK-Gyn is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ICI) therapy on the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).
• women ≥ 18 years of age
• histologically proven metastatic gynecological malignancies irrespective of therapy line
• patients with advanced or metastatic gynecological malignancies must fulfill treatment requirements for ICI therapy in the experimental group
• planned ICI therapy in combination with palliative chemotherapy in the experimental group
• patients with advanced or metastatic gynecological malignancies that undergo chemotherapy without ICIs in the first therapy line in the control group
• written informed consent into ICK-Gyn